Cargando…

Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2 genetic alterations who progressed during or after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Songbai, Burgess, Mike, Major, Christopher, English, Alistair, Sweeney, Maranna, Hartmann, Arndt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339159/ https://www.ncbi.nlm.nih.gov/pubmed/32304281 http://dx.doi.org/10.1002/cjp2.163

Ejemplares similares

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2022)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
por: Monteiro, Fernando Sabino M., et al.
Publicado: (2021)

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
por: Zheng, Xinyi, et al.
Publicado: (2023)

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
por: Deutsch, Alana, et al.
Publicado: (2020)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
por: Lawson‐Michod, Katherine A., et al.
Publicado: (2022)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
por: Poon, Donald, et al.
Publicado: (2021)

Direct conversion of fibroblasts into urothelial cells that may be recruited to regenerating mucosa of injured urinary bladder
por: Inoue, Yuta, et al.
Publicado: (2019)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer
por: POYET, CÉDRIC, et al.
Publicado: (2015)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
por: Meng, Xinmin, et al.
Publicado: (2022)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

MARIJUANA USE AMONG OLDER ADULTS: HARMS MAY OUTWEIGH BENEFITS
por: Choi, Namkee G, et al.
Publicado: (2019)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?
por: Breyer, Johannes, et al.
Publicado: (2017)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
por: Rosumeck, Nathalie, et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function
por: Huynh, Jasmine, et al.
Publicado: (2022)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
por: Finn, Richard S., et al.
Publicado: (2021)

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent
por: Sharma, Padmanee, et al.
Publicado: (2015)

Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma
por: Yanagimoto, Hiroaki, et al.
Publicado: (2020)

Expression of components of the urothelial cholinergic system in bladder and cultivated primary urothelial cells of the pig
por: Leonhäuser, Dorothea, et al.
Publicado: (2019)

Fibroblast Growth Factor-2 and the Invasive Potential in Urothelial Malignancies of the Bladder
por: Popov, Hristo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rn633g6sruhlctc2vqo8pvsr77